(Q36495453)

14 August 2017

1 reference

title

Are there any antirheumatic drugs that modify the course of ankylosing spondylitis? (English)

1 reference

14 August 2017

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80026-3

26 October 2022

author name string

R. Laurent

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1674450

26 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1674450

26 October 2022

publication date

1 August 1990

1 reference

full work available at URL

14 August 2017

https://api.elsevier.com/content/article/PII:S0950357905800263?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80026-3

https://api.elsevier.com/content/article/PII:S0950357905800263?httpAccept=text/plain

26 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80026-3

Bailliere's clinical rheumatology

26 October 2022

published in

1 reference

14 August 2017

volume

4

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

387-400

1 reference

Sulfasalazine and Ankylosing Spondylitis

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Failure of D-penicillamine to affect peripheral joint involvement in ankylosing spondylitis or HLA B27-associated arthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Long term mortality after a single treatment course with X-rays in patients treated for ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Radiotherapy in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Sulphasalazine in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

IgA serum levels and disease activity in ankylosing spondylitis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Evaluation of sulphasalazine in ankylosing spondylitis--an interventional study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Levamisole-induced immunostimulation in spondylarthropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Local radiotherapy for pedal manifestations of HLA-B27-related arthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Favorable results using methotrexate in the treatment of patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Inhibition of antibody secretion by 5-aminosalicylic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Sulphasalazine (Salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Ileocolonoscopic findings in seronegative spondylarthropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Intravenous methylprednisolone pulse therapy in severe ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Immunotherapy with levamisole in rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

A trial of cyclophosphamide in ankylosing spondylitis with involvement of peripheral joints and high disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Correlation of immunoglobulin and C reactive protein levels in ankylosing spondylitis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Penicillamine in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Problems in the assessment of disease activity in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

D-penicillamine in the therapy of ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

RHEUMATOID SPONDYLITIS.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Clinical features and course of ankylosing spondylitis; as seen in a follow-up of 222 hospital referred cases

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980026-3

7 January 2021

Intravenous methylprednisolone pulse therapy in ankylosing spondylitis

16

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80026-3

D-penicillamine in ankylosing spondylitis and polymyositis

26 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80026-3

Intravenous pulsed steroids in rheumatoid arthritis: a comparative dose study

26 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80026-3

Methods of assessment used in ankylosing spondylitis clinical trials: a review

26 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80026-3

C-reactive protein: a marker for disease activity in ankylosing spondylitis and Reiter's syndrome

26 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80026-3

The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis

26 October 2022

40

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80026-3

Treatment of rheumatic disorders with special reference to ankylosing spondylitis

26 October 2022

47

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80026-3

Therapy of the spondyloarthropathies

26 October 2022

48

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80026-3

Penicillamine in ankylosing spondylitis: a double blind placebo controlled trial

26 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80026-3

26 October 2022

Identifiers

1 reference

14 August 2017

1 reference